Als nächstes

Automatisches Abspielen

Novel targets in the treatment of CTCL

2 Ansichten • 08/09/23
Aktie
Einbetten
administrator
administrator
Abonnenten
0

Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, gives an overview of novel drug targets being investigated for the treatment of cutaneous T-cell lymphoma (CTCL), in particular commenting on the CD30 pathway and the role BCL-2. Dr Nicolay also describes synergistic effect of inhibition of BCL-2 in combination with dimethyl fumarate (DMF). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Zeig mehr
0 Bemerkungen sort Sortiere nach
Facebook Kommentare

Als nächstes

Automatisches Abspielen